A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Protagenic Therapeutics, Inc.\new
PTIX
$244K
Mkt Cap
$0.22
+0.00%
Protagenic Therapeutics, Inc.\new (PTIX) has a 5-year average return on invested capital (ROIC) of -64.3%. This is below average and may indicate limited pricing power.
Protagenic Therapeutics, Inc.\new (PTIX) has a market capitalization of $418K. It is classified as a small-cap stock.
Protagenic Therapeutics, Inc.\new (PTIX) does not currently pay a regular dividend.
Protagenic Therapeutics, Inc.\new (PTIX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Protagenic Therapeutics, Inc.\new (PTIX) generated $-4 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Protagenic Therapeutics, Inc.\new (PTIX) has a debt-to-equity ratio of 0.93. This indicates moderate leverage.
Protagenic Therapeutics, Inc.\new (PTIX) reported earnings per share (EPS) of $-4.90 in its most recent fiscal year.
Item 1. Business. Protagenic Therapeutic, Inc. (together with its subsidiary, “Protagenic,” the “Company,” “we,” “our” or “us”) are a biopharmaceutical company specializing in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Our proprietary, patent-protected, first-in-class lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (“TCAP”), an endogenous brain signaling peptide that can dampen overactive stress responses. Our preclinical models have demonstrated efficacy of PT00114 in animal models of depression, anxiety, substance abuse & addiction, and PTSD. PT00114 leverages a completely novel mechanism of action. Protagenic owns exclusive, worldwide rights to PT00114 through its license agreement with the University of Toronto and has an exclusive right to license additional intellectual property generated by Dr. David Lovejoy’s lab at University of Toronto.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | 0 | -5.5M | -5.0M | -3.6M | -4.5M | -2.5M |
| EPS | $0.00 | $-4.90 | $-4.98 | $-14.21 | $-18.22 | $-4.33 |
| Free Cash Flow | 0 | -4.2M | -3.9M | -2.0M | -2.8M | -1.3M |
| ROIC | 0.0% | -444.5% | -97.5% | -50.4% | -44.9% | -229.3% |
| Gross Margin | - | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debt/Equity | 0.00 | 0.93 | 0.18 | 0.04 | 0.01 | -0.94 |
| Dividends/Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | 0 | -5.7M | -4.5M | -3.6M | -4.1M | -2.6M |
| Operating Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| ROE | 0.0% | -236.1% | -94.5% | -42.2% | -102.9% | 285.7% |
| Shares Outstanding | 2M | 1M | 1M | 0M | 0M | 1M |
| Metric | 2013 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | 0.0% | N/A | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | N/A |
| R&D | N/A | 42K | 456K | 418K | 700K | 1.1M | 1.6M | 3.1M | 3.8M | 3.8M |
| SG&A | N/A | 975K | 569K | 1.4M | 1.9M | 3.0M | 2.0M | 1.2M | 1.8M | 1.8M |
| EBIT | N/A | -975K | -1.0M | -2.2M | -2.6M | -4.1M | -3.6M | -4.5M | -5.7M | 0 |
| Op. Margin | 0.0% | N/A | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -1.0M | -1.1M | -1.0M | -2.3M | -2.5M | -4.5M | -3.6M | -5.0M | -5.5M | 0 |
| Net Margin | 0.0% | N/A | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 404K | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||||
| ROIC | N/A | N/M | N/M | -91.9% | N/M | -44.9% | -50.4% | -97.5% | N/M | 0.0% |
| ROE | N/A | N/A | 297.4% | -251.5% | 285.7% | -102.9% | -42.2% | -94.5% | -236.1% | 0.0% |
| ROA | N/A | -438.6% | -796.0% | -143.4% | -296.1% | -75.8% | -37.2% | -80.9% | -176.0% | 0.0% |
| Cash Flow | ||||||||||
| Op. Cash Flow | 0 | -790K | -381K | -1.1M | -1.3M | -2.8M | -2.0M | -3.7M | -4.2M | 0 |
| Free Cash Flow | N/A | -791K | -383K | -1.1M | -1.3M | -2.8M | -2.0M | -3.9M | -4.2M | 0 |
| Owner Earnings | 0 | -1.1M | -860K | -1.7M | -3.0M | -4.3M | -2.9M | -4.4M | -5.2M | -973K |
| CapEx | 0 | 1K | 2K | 0 | 0 | 0 | 2K | 150K | 0 | 0 |
| Maint. CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 28K | 50K | 50K |
| Growth CapEx | N/A | N/A | 2K | N/A | N/A | N/A | 2K | 122K | N/A | 0 |
| D&A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 28K | 50K | 50K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | N/A | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | 0 | 275K | 479K | 546K | 1.7M | 1.5M | 865K | 667K | 923K | 923K |
| Debt Repayment | 0 | 0 | 0 | 0 | 104K | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||||
| Net Debt | N/A | -23K | N/A | N/A | 410K | -10M | -7.7M | N/A | N/A | 4.1M |
| Cash & Equiv. | N/A | 23K | 3K | 3.1M | 671K | 541K | 215K | 1.3M | 1.8M | 2.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | 1.1M | 132K | 151K | N/A | N/A | 3.2M |
| Debt/Equity | N/A | 0.00 | -1.02 | 0.28 | -0.94 | 0.01 | 0.04 | 0.18 | 0.93 | 0.00 |
| Interest Coverage | N/A | -325.0 | -89.3 | -311.9 | -10.4 | -8.3 | -25.9 | -42.0 | N/A | N/A |
| Equity | -121K | -21K | -667K | 2.5M | -1.1M | 9.9M | 6.9M | 3.7M | 1.0M | -2.4M |
| Total Assets | N/A | 246K | 11K | 3.2M | 879K | 11M | 8.0M | 4.3M | 2.0M | 4.4M |
| Total Liabilities | N/A | 267K | 678K | 685K | 2.0M | 1.1M | 1.1M | 655K | 943K | 6.8M |
| Intangibles | N/A | N/A | N/A | 404K | N/A | N/A | N/A | N/A | N/A | 2.1M |
| Retained Earnings | N/A | -1.1M | -6.3M | -8.6M | -18M | -22M | -26M | -31M | -36M | -9.1M |
| Working Capital | N/A | 104K | -675K | 2.5M | 224K | 10M | 6.9M | 3.5M | 940K | -4.5M |
| Current Assets | N/A | 245K | 3K | 3.2M | 879K | 11M | 8.0M | 4.2M | 1.9M | 2.3M |
| Current Liabilities | N/A | 141K | 678K | 685K | 655K | 800K | 1.1M | 655K | 943K | 6.8M |
| Per Share Data | ||||||||||
| EPS | N/A | 0.00 | -98.80 | -7.45 | -4.33 | -18.22 | -14.21 | -4.98 | -4.90 | 0.00 |
| Owner EPS | N/A | N/A | -83.03 | -5.52 | -5.11 | -17.39 | -11.43 | -4.38 | -4.60 | -0.50 |
| Book Value | N/A | N/A | -64.41 | 8.11 | -1.95 | 40.05 | 27.65 | 3.66 | 0.90 | -1.24 |
| Cash Flow/Share | N/A | N/A | -36.81 | -3.73 | -2.29 | -11.27 | -7.97 | -3.69 | -3.74 | 0.03 |
| Dividends/Share | 0.00 | N/A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Shares Out. | N/A | N/A | 0.0M | 0.3M | 0.6M | 0.2M | 0.3M | 1.0M | 1.1M | 1.9M |
| Valuation | ||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Cap | 0 | N/A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 418K |
| Avg. Price | 0.00 | N/A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.22 |
| Year-End Price | 0.00 | N/A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.22 |
Protagenic Therapeutics, Inc.\new passes 0 of 9 quality checks, indicating weak fundamentals.
Protagenic Therapeutics, Inc.\new (PTIX) has a return on equity (ROE) of -236.1%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 9 years of financial data for Protagenic Therapeutics, Inc.\new (PTIX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Protagenic Therapeutics, Inc.\new (PTIX) has a book value per share of $0.90, based on its most recent annual SEC filing.
No recent press releases.